Related Experiment Video

Updated: Aug 18, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Epoprostenol and home mechanical ventilation for pulmonary hypertension associated with chronic lung disease

Ali N Zaidi1, Michael D Dettorre, Gary D Ceneviva

  • 1Department of Internal Medicine and Pediatrics, Penn State Children's Hospital, Pennsylvania State University of Medicine, Hershey, Pennsylvania 17033, USA.

Pediatric Pulmonology
|April 15, 2005
PubMed

Insights

Severe pediatric pulmonary hypertension (PH) and bronchopulmonary dysplasia (BPD) can be fatal. Combining home ventilation with intravenous epoprostenol improved pulmonary artery pressures and quality of life, allowing ventilation discontinuation.

Area of Science:

  • Pediatric Pulmonology
  • Cardiology
  • Critical Care Medicine

Background:

  • Pulmonary hypertension (PH) in infants with bronchopulmonary dysplasia (BPD) is associated with high mortality.
  • Continuous intravenous epoprostenol has demonstrated efficacy in reducing pulmonary artery pressures (PAP) in pediatric idiopathic pulmonary arterial hypertension (PAH).

Observation:

  • This case report details the first instance of combining long-term home ventilation with chronic intravenous epoprostenol in a pediatric patient.
  • The patient presented with severe PH secondary to chronic lung disease.

Findings:

  • The aggressive treatment strategy led to significant reductions in PAP.
  • The patient experienced substantial improvements in quality of life.
  • Home ventilation was eventually discontinued.

Implications:

  • This combined therapeutic approach offers a promising option for managing severe pediatric PH associated with chronic lung disease.
  • Aggressive treatment can improve patient outcomes and potentially reduce long-term healthcare needs.
  • Further research into this combined therapy is warranted for pediatric populations with complex respiratory and cardiovascular conditions.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Mechanical Ventilation III: Noninvasive Ventilation01:23

Mechanical Ventilation III: Noninvasive Ventilation

Noninvasive positive-pressure ventilation (NIPPV), continuous positive airway pressure (CPAP), and bilevel positive airway pressure (BiPAP) are essential methods in respiratory care. These ventilation techniques offer unique benefits for patients with various respiratory conditions, providing adequate support without requiring intubation. Let's explore how each method is crucial in improving patient outcomes and enhancing respiratory therapy.
Noninvasive Positive-Pressure Ventilation (NIPPV)
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation